Brian Archbold - Mesa Laboratories Senior Improvement
| MLAB Stock | USD 142.41 2.44 1.68% |
Executive
Brian Archbold is Senior Improvement of Mesa Laboratories
| Age | 50 |
| Address | 12100 West Sixth Avenue, Lakewood, CO, United States, 80228 |
| Phone | 303 987 8000 |
| Web | https://www.mesalabs.com |
Brian Archbold Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Archbold against Mesa Laboratories stock is an integral part of due diligence when investing in Mesa Laboratories. Brian Archbold insider activity provides valuable insight into whether Mesa Laboratories is net buyers or sellers over its current business cycle. Note, Mesa Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mesa Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Archbold over three months ago Disposition of 1499 shares by Brian Archbold of Mesa Laboratories at 125.0 subject to Rule 16b-3 | ||
Brian Archbold over six months ago Acquisition by Brian Archbold of 889 shares of Mesa Laboratories subject to Rule 16b-3 | ||
Brian Archbold over six months ago Disposition of 420 shares by Brian Archbold of Mesa Laboratories at 142.4 subject to Rule 16b-3 |
Mesa Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0169 % which means that it generated a profit of $0.0169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8946) %, meaning that it created substantial loss on money invested by shareholders. Mesa Laboratories' management efficiency ratios could be used to measure how well Mesa Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.82. The current year's Return On Capital Employed is expected to grow to -0.74. At present, Mesa Laboratories' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 407.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 947.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Philip Binns | Agilent Technologies | N/A | |
| Roland DeAngelis | Vericel Corp Ord | N/A | |
| Michael Moore | Equillium | N/A | |
| Heidi Hassen | Vericel Corp Ord | N/A | |
| Laura Hansen | Denali Therapeutics | N/A | |
| Eric Burns | Vericel Corp Ord | N/A | |
| Penny Tom | Equillium | N/A | |
| Jacquie JD | 23Andme Holding Co | N/A | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Petra Pesendorfer | Valneva SE ADR | 39 | |
| Carole MD | Denali Therapeutics | 52 | |
| Mark Rowen | Denali Therapeutics | N/A | |
| Peter Buhler | Valneva SE ADR | 54 | |
| JuanCarlos MD | Valneva SE ADR | 53 | |
| William Richards | 23Andme Holding Co | 63 | |
| Judson Taylor | Dianthus Therapeutics | N/A | |
| Kristina Maximenko | Dianthus Therapeutics | N/A | |
| Maple MD | Equillium | N/A | |
| Jennifer Low | 23Andme Holding Co | 55 | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Eli Fry | 23Andme Holding Co | N/A | |
Management Performance
| Return On Equity | -0.89 | ||||
| Return On Asset | 0.0169 |
Mesa Laboratories Leadership Team
Elected by the shareholders, the Mesa Laboratories' board of directors comprises two types of representatives: Mesa Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mesa. The board's role is to monitor Mesa Laboratories' management team and ensure that shareholders' interests are well served. Mesa Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mesa Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Dansky, Pres Genomics | ||
| Gary Owens, COO, Vice President | ||
| Brian Archbold, Senior Improvement | ||
| John Sakys, CFO, Chief Accounting Officer and Secretary | ||
| Bryan Leo, VP Operations | ||
| Garrett Krushefski, VP Operations | ||
| John CPA, CFO VP |
Mesa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mesa Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | (1.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 985.26 M | ||||
| Shares Outstanding | 5.43 M | ||||
| Shares Owned By Insiders | 5.74 % | ||||
| Shares Owned By Institutions | 93.94 % | ||||
| Number Of Shares Shorted | 193.96 K | ||||
| Price To Earning | 433.94 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mesa Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesa Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesa Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesa Laboratories Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.875 | Dividend Share 0.64 | Earnings Share (45.61) | Revenue Per Share | Quarterly Revenue Growth 0.088 |
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.